Thursday, 06 June 2013
The Royal College of Pathologists, Carlton House Terrace, London, SW1Y 5AF, United Kingdom
This event is discussion forum, focused on clinical applications of stem cell therapy. The aim is to offer participants a chance to explore aspects with the experts during round table and one-to one discussions.
Meeting Chair: Dr Glyn Stacey, UK Stem Cell Bank, Division of Cell Biology and Imaging.
This event has CPD accreditation and is part of the 2013 Euroscicon Stem Cell Trilogy.
To find out more see www.stemcells2013.com
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chair: Dr Glyn Stacey, UK Stem Cell Bank, Division of Cell Biology and Imaging.
10:00 – 10:20 First-in-Man trials of Stem Cells as Medicines – from single cells to 3-D constructs
Dr Mark Lowdell, University College London, UK
10:20 – 10:40 Biologic Augmentation of Rotator Cuff Repairs
Dr. James Hoffman, Coordinated Health, USA
Recurrent rotator cuff tears are a well documented problem. Following surgical correction, healing of the rotator cuff is impeded by muscle atrophy, fat infiltration, devascularization, and scar tissue formation. The structural integrity of the tendon is weakened, increasing the susceptibility to retear. Consequently, biologic adjuvants and mechanical reinforcements have been suggested as a means of recreating a biomechanically equivalent layer of connective tissue. Within, we present our initial clinical and histological findings evaluating the efficacy of a rotator cuff repair performed with platelet-rich plasma, a dermal allograft, and mesenchymal stem cells.
10:40 – 11:00 Generating hESCs for Clinical Application: The Challenges for Academics.
Dr Zoe Hewitt, Centre for Stem Cell Biology, The University of Sheffield
As momentum in the field of human embryonic stem cell (hESC) based therapies grows, researchers face the challenge of developing raw materials from which these therapies can be developed which are suitable for clinical application. Consequently, there has been significant emphasis placed on deriving new hESC lines using good manufacturing practices (GMPs) to provide standard mechanisms for assessing reliability and reproducibility of these raw materials. If GMP standards are to be met, the derivation process, which involves a range of procedures and mechanisms some of which are not yet fully understood, must be validated and implemented in a framework of strict quality management.
11:00 – 11:30 Speakers’ photo then mid-morning break, poster sessions and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:30 – 11:50 A risk based, unit operation approach to manufacturing process science for cell based therapies
Dr Robert Thomas, Loughborough University, UK
The EPSRC Centre for Innovative Manufacturing in Regenerative Medicine is developing manufacturing science for industrial production of advanced therapies. Key goals are reduction of risk and cost in translating development therapies to commercially viable products. Important steps include early process analysis, consideration of constituent units of operation, and risk assessment in the context of industrial operating restrictions and logistics. Key challenges such as identifying units of operation, required measurement system performance and frequency for process control, and application of engineering design for optimisation, risk reduction, and decision making, will be discussed with examples from both academic and commercial development programmes.
11:50 – 12:10 The clinician-scientist - professional dynamics in stem cell research
Dr. Dana Wilson-Kovacs, Department of Sociology, Philosophy and Anthropology, University of Exeter, UK
The clinician-scientist, a professional who straddles research and therapy and possesses both medical and scientific expertise, is key to bringing novel biomedical applications into the clinic. Focusing on a case study of British and German medical teams engaged in double-blind randomised clinical trials using patients’ own stem cells for heart repair, this talk explores the experiences of a small number of clinician-scientists working in the stem cell field, and the ways in which these professionals portray, explain and justify their role in the wider clinical research environment.
12:10 – 12:30 Stem cell treatment for multiple sclerosis
Professor Neil Scolding, Burden Professor of Clinical Neurosciences, University of Bristol, UK
Multiple sclerosis (MS) is a major cause of disability, particularly affecting young adults, in which patches of tissue damage occur throughout the brain and spinal cord. Recent advances in our understanding of how MS progresses have radically altered the way we think about cell therapy for this disease. The many and varied reparative properties of bone marrow derived stem cells may offer new and attractive possibilities for developing cell-based treatments for MS, with significant and positive implications also for other common neurodegenerative conditions.
12:30 – 13:30 Lunch, poster sessions and trade show Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
Oral Presentations
13:30 – 13:45 HUMAN FETAL DOPAMINERGIC PRECURSOR CELL TRANSPLANTATION: LIF-NANOTHERAPY TO PROMOTE (i) IMMUNE TOLERANCE, AND (ii) GRAFT SURVIVAL.
Metcalfe Su M.Brain Repair Centre, Addenbrooke’s Hospital, Cambridge, CB2 0PQ, UK.
13:45 – 14:00 IMMUNOLOGICAL EFFECTS OF MESENCHYMAL STROMAL CELLS ON T CELL LINES FROM
CROHN’S DISEASE PATIENTS
R. Ciccocioppo, Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Piazzale Golgi, 19; 27100 Pavia; Italy
14:00 – 16:00 Round Table Discussions
Table 1: Mark Lowdell
Table 2: Professor Neil Scolding
Table 3: Robert Thomas
Table 4: Zoe Hewitt
Table 5: James Hoffman
16: 00 - 16:30 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day
16:30 – 17:00 Chairman’s summing up
About the Chair
Glyn Stacey, Head of the Division of Cell Biology and Imaging at NIBSC and Director for the UK Stem Cell Bank.
His scientific background has been in microbiology and cancer research. From 1989-1998 he worked at Porton Down, UK, where he developed cell banking procedures and the development of cells for manufacture of medical products and cell-based diagnostic assays. At NIBSC he has developed a broad remit relating to the quality and safety of new biological medicines and therapies based on the use of human and animal cells. He has also acted as an advisor to the UK Department of Health and the World Health Organization. He coordinates the International Stem Cell Banking Initiative funded by a consortium of funding agencies from 20 countries. He has recently overseen the establishment of a new and expanded GMP facility for banking stem cell lines. He has published numerous scientific papers and books on cell banking and quality control.
About the Speakers
Neil Scolding trained in neurology in Cardiff, Cambridge and London (National Hospital for Neurological Diseases), before being appointed foundation Burden Professor of Clinical Neurosciences at the University of Bristol and Frenchay Hospital. His main clinical research interests lie in multiple sclerosis and other inflammatory neurological diseases, and the biology and clinical development of stem cell therapies for MS and other neurodegenerative conditions. He has published four textbooks and some 150 research papers; is currently a Guarantor of the journal Brain; and is a member of the editorial board of various other journals, of the national bioethics committee ESBAC, and of the Association of British Neurologists Council.
Dana Wilson-Kovacs is a lecturer in the Department of Sociology, Philosophy and Anthropology at the University of Exeter. She is a sociologist interested in the socio-cultural transformations brought about by biomedical and biotechnological innovations. Her writing on regulation, clinical trials and professional dynamics in stem cell research has been published in journal such as Sociology of Health and Illness, New Genetics and Society and Innovation: The European Journal of Social Sciences.
Following Zoe Hewitt ‘s PhD at the Roslin Insitute in Edinburgh, where she studied the “elimination of undifferentiated human embryonic stem cells in vitro” as a method to address the associated risk of tumorgenicity from the accidental transplantation of undifferentiated hESCs within a therapeutic graft, Zoe moved to the Stem Cell Derivation Facility (SCDF) at the Centre for Stem Cell Biology, University of Sheffield to take up a role as Quality Manager. Since 2006 she has been responsible for commissioning and managing a Clean Room Facility for the production of clincal grade human embryonic stem cells with a goal of making these available for use in future therapeutics.
Rob Thomas is a Senior Lecturer and EPSRC Bio-manufacturing Fellowship holder at Loughborough University. He is a leading member of the bio-manufacturing research team working to develop the process science and the manufacturing capability for cell based regenerative medicine therapies, with a particular focus on haematopoietic lineage based processes. He is currently associate director of the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine led from the Centre for Biological Engineering at Loughborough University.
Event Web Site: www.regonline.co.uk/stem2013
Post expires at 7:47am on Thursday June 6th, 2013
Follow Us!